Cellular microenvironment as an object of targeted therapy for malignant neoplasms

Cover Page

Cite item

Full Text

Abstract

The dynamic relationships between tumor cells and their microenvironment are of crucial importance in the development and progression of the malignant process. Given the multifunctional potential of heterogeneous populations surrounding a tumor, targeting components of the microenvironment has long been regarded as a promising strategy in modern anticancer therapy. This review discusses the role of the components of the cellular microenvironment in carcinogenesis, analyzes in detail the main ways and mechanisms of action on the main cell populations, which are of the greatest interest in the context of the development of innovative anticancer therapy.

About the authors

E. Yu. Zyablitskaya

S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University

Author for correspondence.
Email: evgu79@mail.ru
ORCID iD: 0000-0001-8216-4196

Evgenia Yu. Zyablitskaya.

Bld. 7, 5 Lenin Boulevard, Simferopol 295051

Russian Federation

A. V. Kubyshkin

S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University

Email: fake@neicon.ru
ORCID iD: 0000-0002-9400-1826

Bld. 7, 5 Lenin Boulevard, Simferopol 295051

Russian Federation

L.  E. Sorokina

S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University

Email: fake@neicon.ru
ORCID iD: 0000-0002-1862-6816

Bld. 7, 5 Lenin Boulevard, Simferopol 295051

Russian Federation

A. V. Serebryakova

S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University

Email: fake@neicon.ru
ORCID iD: 0000-0002-1048-5158

Bld. 7, 5 Lenin Boulevard, Simferopol 295051

Russian Federation

K.  A. Aliev

S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University

Email: fake@neicon.ru
ORCID iD: 0000-0003-3911-1245

Bld. 7, 5 Lenin Boulevard, Simferopol 295051

Russian Federation

P.  E.  Maksimova

S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University

Email: fake@neicon.ru
ORCID iD: 0000-0001-5920-8664

Bld. 7, 5 Lenin Boulevard, Simferopol 295051

Russian Federation

A. E. Lazarev

S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University

Email: fake@neicon.ru
ORCID iD: 0000-0003-2684-3834

Bld. 7, 5 Lenin Boulevard, Simferopol 295051

Russian Federation

A. I.  Balakchina

S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University

Email: fake@neicon.ru
ORCID iD: 0000-0001-6239-885X

Bld. 7, 5 Lenin Boulevard, Simferopol 295051

Russian Federation

I. O.  Golovkin

S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University

Email: fake@neicon.ru
ORCID iD: 0000-0002-3578-5130

Bld. 7, 5 Lenin Boulevard, Simferopol 295051

Russian Federation

References

  1. Koontongkaew S. The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J Cancer 2013;4(1):66–83. doi: 10.7150/jca.5112
  2. Zibirov R.F., Mozerov S.A. Characterization of the tumor cell microenvironment. Onkologiya. Zhurnal im. P.A. Gercena = P.A. Herzen Journal of Oncology 2018;7(2):67–72. (In Russ.). doi: 10.17116/onkolog20187267-72
  3. Ataei A., Solovyeva V.V., Rizvanov A.A., Arab S.Sh. Tumor microenvironment: a key contributor to cancer progression, invasion, and drug resistance. Uchenye Zapiski Kazanskogo Universiteta. Seriya Estestvennye Nauki = Scientific notes of Kazan University. Series “Natural Sciences” 2020;162:507–28. (In Russ.). doi: 10.26907/2542-064X.2020.4.507-528
  4. Krahmal’ N.V., Zav’jalova M.V., Denisov E.V. et al. Invasion of tumor epithelial cells: mechanisms and manifestations. Acta Naturae 2015;7(2):18–31. (In Russ.).
  5. Dudley A.C. Tumor endothelial cells. Cold Spring Harb Perspect Med 2012;2(3):a006536. doi: 10.1101/cshperspect.a006536
  6. Baghban R., Roshangar L., Jahanban-Esfahlan R. et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal 2020;18(1):59. doi: 10.1186/s12964-020-0530-4
  7. Gille H., Kowalski J., Li B. et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2): a reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001;276:3222–30. doi: 10.1074/jbc.M002016200
  8. Daei Farshchi Adli A., Jahanban-Esfahlan R., Seidi K. et al. An overview on Vadimezan (DMXAA): The vascular disrupting agent. Chem Biol Drug Des 2018;91(5):996–1006. doi: 10.1111/cbdd.13166
  9. Zhang Y., Xiong X., Huai Y. et al. Gold nanoparticles disrupt tumor microenvironment – endothelial cell cross talk to inhibit angiogenic phenotypes in vitro. Bioconjug Chem 2019;30(6):1724–33. doi: 10.1021/acs.bioconjchem.9b00262
  10. Nomura T., Yamakawa M., Shimaoka T. et al. Development of dendritic cell-based immunotherapy targeting tumor blood vessels in a mouse model of lung metastasis. Biol Pharm Bull 2019;42(4):645–8. doi: 10.1248/bpb.b18-00737
  11. Liu T., Zhou L., Li D. et al. Cancer-associated fibroblasts build and secure the tumor microenvironment. Front Cell Dev Biol 2019;7:60. doi: 10.3389/fcell.2019.00060
  12. Puré E., Hingorani S.R. Mesenchymal cell plasticity and perfidy in epithelial malignancy. Trends Cancer 2018;4(4):273–7. doi: 10.1016/j.trecan.2018.02.007
  13. Shiga K., Hara M., Nagasaki T. et al. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers 2015;7(4):2443–58. doi: 10.3390/cancers7040902
  14. Ermakov M.S., Nushtaeva A.A., Richter V.A., Koval O.A. Cancer-associated fibroblasts and their role in tumor progression. Vavilovskii Zhurnal Genetiki i Selektsii = Vavilov Journal of Genetics and Breeding 2022;26(1):14–21. (In Russ.). doi: 10.18699/VJGB-22-03
  15. Hosein A.N., Wu M., Arcand S.L. et al. Breast carcinoma-associated fibroblasts rarely contain p53 mutations or chromosomal aberrations. Cancer Res 2010;70(14):5770–7. doi: 10.1158/0008-5472.CAN-10-0673
  16. Oleynikova N.А., Danilova N.V., Mikhailov I.A. et al. Cancer-associated fibroblasts and their significance in tumor progression. Arkhiv Patologii = Pathology Archive 2020;82(1):68–77. (In Russ.). doi: 10.17116/patol20208201168
  17. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer 2016;16(9):582–98. doi: 10.1038/nrc.2016.73
  18. Monteran L., Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol 2019;10:1835. doi: 10.3389/fimmu.2019.01835
  19. Jones J.O., Moody W.M., Shields J.D. Microenvironmental modulation of the developing tumor: an immune-stromal dialogue. Mol Oncol 2021;15(10):2600–33. doi: 10.1002/1878-0261.12773
  20. Pavlides S., Whitaker-Menezes D., Castello-Cros R. et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009;8(23):3984–4001. doi: 10.4161/cc.8.23.10238
  21. Jiang G.M,. Xu W., Du J. et al. The application of the fibroblast activation protein alpha-targeted immunotherapy strategy. Oncotarget 2016;7(22):33472–82. doi: 10.18632/oncotarget.8098
  22. Yoshida T., Ishii G., Goto K. et al. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. Clinl Cancer Res 2015;21(3):642–51. doi: 10.1158/1078-0432.CCR-14-0846
  23. Noy R., Pollard J.W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014;41(1):49–61. doi: 10.1016/j.immuni.2014.06.010
  24. Laviron M., Boissonnas A. Ontogeny of tumor-associated macrophages. Front Immunol 2019;10:1799. doi: 10.3389/fimmu.2019.01799
  25. Mantovani A., Sica A., Sozzani S. et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25(12):677–86. doi: 10.1016/j.it.2004.09.015
  26. Nesbit M., Schaider H., Miller T.H., Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 2001;166(11):6483–90. doi: 10.4049/jimmunol.166.11.6483
  27. Porta C., Subhra Kumar B., Larghi P. et al. Tumor promotion by tumor-associated macrophages. Adv Exp Med Biol 2007;604: 47–86. doi: 10.1007/978-0-387-69116-9_5
  28. Valkovic T., Dobrila F., Melato M. et al. Correlation between vascular endothelial growth factor, angiogenesis and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch 2002;440(6):583–8. doi: 10.1007/s004280100458
  29. Chen Y., Tan W., Wang C. Tumor-associated macrophage-derived cytokines enhance cancer stem-like characteristics through epithelial-mesenchymal transition. Onco Targets Ther 2018;11:3817–26. doi: 10.2147/OTT.S168317
  30. Mantovani A., Marchesi F., Malesci A. et al. Tumor-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017;14(7):399–416. doi: 10.1038/nrclinonc.2016.217
  31. Van Rooijen N., Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994;174(1–2):83–93. doi: 10.1016/0022-1759(94)90012-4
  32. Banciu M., Metselaar J.M., Schiffelers R.M., Storm G. Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. Neoplasia 2008;10(2):108–17. doi: 10.1593/neo.07913
  33. Sato K., Fujita S. Dendritic cells: nature and classification. Allergol Int 2007;56(3):183–91. doi: 10.2332/allergolint.R-06-139
  34. Oleinik E.K., Shibaev M.I., Ignatiev KS. et al. Tumor microenvironment: the formationof the immune profile. Medicinskaya immunologiya = Medical Immunology. 2020;22(2):207–20. (In Russ.). doi: 10.15789/1563-0625-TMT-1909
  35. Shurin M.R., Yurkovetsky Z.R., Tourkova I.L. Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int J Cancer 2002;101(1):61–8. doi: 10.1002/ijc.10576
  36. Manavalan J.S., Rossi P.C., Vlad G. et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 2003;11(3–4):245–58. doi: 10.1016/s0966-3274(03)00058-3
  37. Liu Q., Zhang C., Sun A. et al. Tumor-educated CD11 bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J Immunol 2009;182(10):6207–16. doi: 10.4049/jimmunol.0803926
  38. Anandasabapathy N., Victora G.D., Meredith M. et al. Flt3L controls the development of radiosensitive dendritic cells in the meninges and choroid plexus of the steady-state mouse brain. J Exp Med 2011;208(8):1695–705. doi: 10.1084/jem.20102657
  39. Salmon H., Idoyaga J., Rahman A. et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 2016;44(4):924–38. doi: 10.1016/j.immuni.2016.03.012
  40. Anandasabapathy N., Breton G., Hurley A. et al. Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant 2015;50(7):924–30. doi: 10.1038/bmt.2015.74
  41. Agrawal V., Benjamin K.T., Ko E.C. Radiotherapy and immunotherapy combinations for lung cancer. Curr Oncol Rep 2020;23(1):4. doi: 10.1007/s11912-020-00993-w
  42. Anguille S., Smits E.L., Lion E. et al. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014;15(7):e257–67. doi: 10.1016/s1470-2045(13)70585-0
  43. Jiang Y., Li Y., Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis 2015;6(6):e1792. doi: 10.1038/cddis.2015.162
  44. Chang C.H., Curtis J.D., Maggi L.B. et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 2013;153(6):1239–51. doi: 10.1016/j.cell.2013.05.016
  45. Fife B.T., Bluestone J.A. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008;224:166–82. doi: 10.1111/j.1600-065X.2008.00662.x
  46. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271(5256):1734–6. doi: 10.1126/science.271.5256.1734
  47. Kwon E.D., Hurwitz A.A., Foster B.A. et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 1997;94(15):8099–103. doi: 10.1073/pnas.94.15.8099
  48. Hurwitz A.A., Yu T.F., Leach D.R., Allison J.P. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 1998;95(17):10067–71. doi: 10.1073/pnas.95.17.10067
  49. Hodi F.S., O’Day S.J., McDermott D.F. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711–23. doi: 10.1056/NEJMoa1003466
  50. Weber J.S., D’Angelo S.P., Minor D. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16(4):375–84. doi: 10.1016/S1470-2045(15)70076-8
  51. Robert C., Schachter J., Long G.V. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372(26):2521–32. doi: 10.1056/NEJMoa1503093
  52. Robert C., Long G.V., Brady B. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372(4):320–30. doi: 10.1056/NEJMoa1412082
  53. Gong J., Chehrazi-Raffle A., Reddi S., Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 2018;6(1):8. doi: 10.1186/s40425-018-0316-z
  54. Mann J.E. Atezolizumab (tecentriq®). Oncology Times 2017;39(4):31. doi: 10.1097/01.cot.0000513325.52233.f1
  55. Zlatnik E.Yu., Sitkovskaja A.O., Nepomnjashhaja E.M. et al. Achievements and prospects of cellular technologies based on activated lymphocytes in the treatment of malignant tumors. Kazanskij medicinskij zhurnal = Kazan Medical Journal 2018;99(5):792–801. (In Russ.). doi: 10.17816/KMJ2018–792
  56. Rosenberg S.A., Mulé J.J., Spiess P.J. et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985;161(5):1169–88. doi: 10.1084/jem.161.5.1169
  57. Jackson H.J., Rafiq S., Brentjens R.J. Driving CAR T-cells forward. Nat Rev Clin Oncol 2016;13(6):370–83. doi: 10.1038/nrclinonc.2016.36
  58. Ustjugova E.A., Savkina M.V., Gorjaev A.A. et al. The use of biomedical cell products for the treatment of oncological diseases. BIO-preparaty. Profilaktika, diagnostika, lechenie = BIO medication. Prevention, diagnosis, treatment 2019;19(4):206–14. (In Russ.). doi: 10.30895/2221-996X-2019-19-4-206-214
  59. Chang Z.L., Lorenzini M.H., Chen X. et al. Rewiring T-cell responses to soluble factors with chimeric antigen receptors. Nat Chem Biol 2018;14(3):317–24. doi: 10.1038/nchembio.2565
  60. Hartmann J., Schüßler-Lenz M., Bondanza A., Buchholz C.J. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med 2017;9(9):1183–97. doi: 10.15252/emmm.201607485

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 57560 от  08.04.2014.